Back To: Home

January 19-23, 2015
PepTalk - San Diego, CA

February 7-11, 2015
SLAS2015 - Washington, DC

More Events

Jubilant announces collaboration with Mnemosyne
April 2012

BANGALORE, India—A new drug discovery collaboration was established last month between Jubilant Biosys Ltd. and Mnemosyne Pharmaceutical Inc. focused on identifying preclinical candidates in neuropsychiatric diseases. The companies will work to develop subunit selective NMDA receptor modulators (SNRMs) identified by Mnemosyne, and the collaboration will initially run for two years, though it can be extended by mutual consent across other therapeutic areas. Per the terms of the agreement, Mnemosyne will have exclusive ownership of all intellectual property generated and will be responsible for clinical development and commercialization within the partnership.  
"We are looking forward to a successful collaboration with Jubilant that will produce first-in-class drugs that address the unmet medical need in neuropsychiatric diseases such as schizophrenia and Alzheimer's disease," Dr. Kollol Pal, CEO of Mnemosyne, said in a press release.


Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
© Copyright 2014 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.